Last reviewed · How we verify
Reducing dose of Lopinavir
Lopinavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and thereby inhibiting HIV replication.
Lopinavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and thereby inhibiting HIV replication. Used for HIV-1 infection (in combination with ritonavir and other antiretroviral agents).
At a glance
| Generic name | Reducing dose of Lopinavir |
|---|---|
| Sponsor | University Hospital, Geneva |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Lopinavir binds to the active site of HIV protease, a viral enzyme essential for processing precursor polyproteins into mature, functional viral proteins. By preventing this proteolytic cleavage, lopinavir causes the production of immature, non-infectious viral particles. This mechanism is the basis for its antiretroviral activity, and dose reduction is typically employed to minimize toxicity while maintaining therapeutic efficacy, often in combination with other antiretroviral agents.
Approved indications
- HIV-1 infection (in combination with ritonavir and other antiretroviral agents)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Lipid abnormalities (elevated triglycerides and cholesterol)
- Hepatotoxicity
- Hyperglycemia
Key clinical trials
- First in Human Study of TLC-ART 101 (ACTU 2001) (PHASE1)
- Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19 (PHASE3)
- Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth (PHASE2)
- Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1" (PHASE3)
- Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 (PHASE2)
- Trial to Study the Benefit of Colchicine in Patients With COVID-19 (PHASE3)
- Dose Reduction of Lopinavir in Children (PHASE2)
- Lopinavir (LPV) Dose Reduction (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reducing dose of Lopinavir CI brief — competitive landscape report
- Reducing dose of Lopinavir updates RSS · CI watch RSS
- University Hospital, Geneva portfolio CI